Melanoma Metastatic Clinical Trials

21 clinical trials for Melanoma Metastatic across international registries, including 11 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma — RECRUITING · PHASE2
• Dietary Fiber to Induce Gut Microbiota-mediated Response to Immunotherapy in Melanoma. — RECRUITING · PHASE2
• A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors. — RECRUITING · PHASE2
• NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma — RECRUITING · PHASE1
• Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma — RECRUITING · PHASE2
• A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma — RECRUITING · PHASE1
• Study to Evaluate Impact® as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperable Locally Advanced or Metastatic Melanoma — RECRUITING · NA
• Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma Study — RECRUITING · NA
• Observational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can Predict Response to Immunotherapy. — RECRUITING
• T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma — RECRUITING · PHASE1
• Neoadjuvant Immunotherapy of Operable Metastatic Melanoma in Real Life (GCC) — RECRUITING
• A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma — NOT_YET_RECRUITING · PHASE2
• PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor — NOT_YET_RECRUITING
• Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS) — ACTIVE_NOT_RECRUITING · PHASE2
• Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma — ACTIVE_NOT_RECRUITING · PHASE1
• A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma — ACTIVE_NOT_RECRUITING · PHASE3
• Surgery for Gastrointestinal Metastases of Malignant Melanoma - a Single Center Retrospective Cohort Study — COMPLETED
• Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma — OTHER · PHASE2
• To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. — OTHER · PHASE2
• Interleukin-2 in Metastatic Melanoma — TERMINATED · PHASE2
• Dacarbazine and Carmustine in Metastatic Melanoma — TERMINATED · PHASE2

Refine this search